Neuromuscular Toxicities of Paclitaxel
Author Information
Author(s): H Kunitoh, N Saijo, K Furuse, K Noda, M Ogawa
Primary Institution: National Cancer Center Hospital, Tokyo, Japan
Hypothesis
What are the risk factors for neuromuscular toxicity associated with paclitaxel given by a 3-hour infusion?
Conclusion
Neuromuscular toxicity from paclitaxel is dependent on the cumulative dose but cannot be predicted from baseline patient characteristics.
Supporting Evidence
- Neuromuscular toxicity showed a significant correlation with the total cumulative dose of paclitaxel.
- The severity of myalgia/arthralgia was graded, with most patients experiencing at least grade 1.
- Peripheral neuropathy was often persistent, while myalgia/arthralgia was usually completely reversible.
Takeaway
This study looked at how paclitaxel affects muscles and nerves in cancer patients. It found that the more medicine you get, the more likely you are to feel side effects, but doctors can't always tell who will have problems just by looking at them.
Methodology
A retrospective analysis of four phase II trials involving 247 patients receiving paclitaxel.
Limitations
The study is retrospective and may not account for all variables affecting toxicity.
Participant Demographics
{"primary_tumour":{"Lung (non small cell)":120,"Breast":62,"Ovary":65},"sex":{"Male":94,"Female":153},"median_age":{"value":60,"range":"21-74"},"performance_status":{"0":92,"1":127,"2":28},"metastatic_site":{"Brain":13,"Bone":55,"Liver":48,"Pleural effusion":38,"Ascites":2},"prior_chemotherapy":{"None":120,"Non-cisplatin":65,"Cisplatin containing":62}}
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website